

## PATENT, TRADEMARK AND DESIGN ATTORNEYS

## **Decision G2/08 of the Enlarged Board of Appeal of the EPO**

## "Swiss-type-Claim" format not longer allowed!

In G 2/08, the Enlarged Board of Appeal of the EPO has held that in cases where a claim is directed to a second or further medical use, i.e. the subject of a claim is rendered novel only by a new therapeutic use, such claim should no longer be written in the so-called "Swiss-type claim" format like >>Use of compound X for the manufacture of a pharmaceutical composition for the treatment of disease Y<<.

Pending applications are not affected by this decision. The relevant date for future applications is their date of filing or, if priority has been claimed, their earliest priority date. Therefore, European patents containing a Swiss-type claim and having a filing date or earliest priority date of January 29<sup>th</sup>, 2011 or later will not be granted.

In the future, applicants might use the following format of a purpose-related product claim:

"Composition comprising active agent X for use in the treatment of disease Y".

Additionally, the Enlarged Board of Appeal established in this decision directed to claims relating to a second or further medical use, the following head note:

"Such patenting is also not excluded where a dosage regime is the only feature claimed which is not comprised in the state of the art."

## Disclaimer

This information letter contains general information about the amendments of Implementing Regulations to the EPC which could be of interest to our clients and foreign firms and their clients. This is not a legal advice. Additionally, the actual implementation of the amendments by the EPO has not been fully clarified as yet. Therefore, we cannot provide and take over any warranty and liability for the provided information and for the consequences following any action made due to the information provided in these letters. Please do not hesitate to contact us for further information and also a legal advice or expert opinion which might be charged according to our regular schedule of fees.

mail@ABK-IP.com Tel.: 030-330072-330 Fax: 030-30111-676 www.ABK-IP.com